---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-25-000002"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:57:07.132070+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Xencor: $707M cash; XmAb541 selectivity; plamotamab B-cell depletion; XmAb808 dose escalation; vudalimab enrollment done

## Summary
- Preliminary cash & marketable securities ~$707M at Dec 31, 2024, up from $697M in 2023; expected to fund ops into 2028.
- New preclinical data shows XmAb541 (CLDN6 x CD3) selective binding to CLDN6 over CLDN9.
- Plamotamab (CD20 x CD3) Phase 1 data shows deep peripheral B-cell depletion in lymphoma patients.
- XmAb808 (B7-H3 x CD28) has resumed dose escalation in clinical study.
- Enrollment completed in three ongoing vudalimab (PD-1 x CTLA-4) studies.

## SEC filing metadata
- accession: 0001326732-25-000002
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000002/0001326732-25-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000002/xncr-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-25-000002
- JSON: https://secwatch.observer/filing/0001326732-25-000002.json
- Plain text: https://secwatch.observer/filing/0001326732-25-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.